Sphere Fluidics was founded in 2010 and is an established Life Sciences company, originally spun out from the University of Cambridge. The company initially focused on producing novel biochip systems and providing R&D services. Their systems make the development of new biopharmaceuticals faster and more cost-effective, improve monoclonal antibody screening, cell line development, and overall research efficiency in a number of other applications including synthetic biology, single cell diagnostics, prognostics and single cell genome editing. The Cyto-Mine® Single Cell Analysis System is the flagship product of Sphere Fluidics: the first integrated, benchtop system to automatically analyze, sort and dispense millions of individual cells in just a single day.
More about Sphere Fluidics: https://spherefluidics.com